Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Harvard Business School
Baxter
McKinsey
Boehringer Ingelheim

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,403,569

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,403,569 protect, and when does it expire?

Patent 6,403,569 protects CAMPTOSAR and is included in one NDA.

Protection for CAMPTOSAR has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has two patent family members in two countries.

Summary for Patent: 6,403,569
Title: Method for treating cancer using camptothecin derivatives and 5-fluorouracil
Abstract:A combination therapy for treating cancer including administering at least one camptothecin derivative in conjunction with another anticancer agent. The combination therapy is preferably used as a first-line therapy for treating metastatic colorectal cancer and preferably involves administration of a combination of CPT-11, 5-fluorouracil and folinic acid, according to specific infusional treatment schedules which show therapeutic synergy in the treatment of cancer.
Inventor(s): Achterrath; Wolf R. (Dectzenbach, DE)
Assignee: Aventis Pharma S.A. (Antony, FR)
Application Number:09/559,737
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 6,403,569

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pfizer Inc CAMPTOSAR irinotecan hydrochloride INJECTABLE;INJECTION 020571-001 Jun 14, 1996 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Pfizer Inc CAMPTOSAR irinotecan hydrochloride INJECTABLE;INJECTION 020571-002 Jun 14, 1996 AP RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Express Scripts
McKesson
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.